Vaccine Adjuvants Market is projected to grow from USD 1.5 billion in 2022 to USD 1.6 billion by 2027, at a CAGR of 1.7% from 2022 to 2027, according to a new report by MarketsandMarkets™. The growth of the market is projected to be driven by collaborations and partnerships among market players for the development of vaccine adjuvants, an increasing number of COVID-19 vaccines in the development pipeline and increasing focus on immunization programs.
What are Vaccine Adjuvants and What Do They Do?
Vaccine adjuvants are substances added to vaccines to boost their efficacy. They work by stimulating the body’s immune system to produce a stronger immune response after vaccination. By doing so, adjuvants can help the body recognize and fight off the disease. Vaccine adjuvants can also extend the duration of protection, reduce the number of doses needed, and help protect against emerging and reemerging diseases.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894
What Factors are Driving Growth in the Vaccine Adjuvants Market?
The vaccine adjuvants market is growing rapidly due to the increasing demand for safer and more effective vaccines, advancements in adjuvant technologies, and a growing awareness of the importance of immunization. The emergence of new and re-emerging infectious diseases, such as COVID-19, has also increased the demand for adjuvants. Additionally, the increasing prevalence of chronic diseases, such as cancer and diabetes, has prompted the development of new adjuvants for therapeutic vaccines. Finally, the rise in government funding for vaccine development and the increasing investments from pharmaceutical companies are also contributing to the growth of the vaccine adjuvants market.
What are the Different Types of Vaccine Adjuvants?
Vaccine adjuvants can be divided into two categories: chemical and biological. Chemical adjuvants include aluminum salts, such as aluminum hydroxide and aluminum phosphate; synthetic compounds, such as squalene and polysorbates; and oil-in-water emulsions, such as MF59 and AS03. Biological adjuvants include bacteria, viruses, and plant extracts.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894
What are the Key Players in the Vaccine Adjuvants Market?
The vaccine adjuvants market is highly competitive, with several key players. Key players in the vaccine adjuvants market include GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia).
What are the Future Trends in the Vaccine Adjuvants Market?
The vaccine adjuvants market is expected to continue to grow in the coming years due to the emergence of new and re-emerging infectious diseases, the increasing prevalence of chronic diseases, and advancements in adjuvant technologies. Additionally, the development of combination vaccines, as well as the increasing demand for personalized vaccines, is also expected to drive growth in the market. The increasing investments in vaccine research and development, and the rise in government funding for vaccine development are expected to further boost the growth of the vaccine adjuvants market.
This report categorizes the vaccine adjuvants market into the following segments and subsegments
- Adjuvant Emulsions
- Pathogen Components
- Saponin-baased adjuvants
- Particulate Adjuvants
- Other Adjuvants
By Route of Administration
- Other Route of Administration
By Disease Type
- Infectious Diseases
- Research Applications
- Commercial Applications
By Application Category
- Human Vaccine Adjuvants
- Veterinary Vaccine Adjuvants
- North America
- Asia Pacific
- Latin America
- Middle East Africa
- Dynavax Technologies (US) entered into a fully funded collaboration with the US Department of Defense to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018.
- SK Bioscience (South Korea)and GSK plc (UK)entered into a collaboration for COVID-19 vaccine development.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062